COVID-19 vaccine clinical research
Clinical research to establish the characteristics of COVID-19 vaccines / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about COVID-19 vaccine clinical research?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022[update], 40 vaccines are authorized by at least one national regulatory authority for public use:[1][2]
- one DNA vaccine: ZyCoV-D[3]
- four RNA vaccines: Pfizer–BioNTech,[4] Moderna,[5] Walvax, and Gemcovac
- twelve inactivated vaccines: Chinese Academy of Medical Sciences,[6][7] CoronaVac,[6] Covaxin,[6] CoviVac, COVIran Barekat, FAKHRAVAC, Minhai-Kangtai, QazVac, Sinopharm BIBP,[6] WIBP, Turkovac, and VLA2001.[6]
- six viral vector vaccines: Sputnik Light, Sputnik V, Oxford–AstraZeneca, Convidecia, Janssen, and iNCOVACC
- sixteen subunit vaccines: Abdala, Corbevax,[6] COVAX-19, EpiVacCorona, IndoVac, MVC-COV1901,[6] Noora, Novavax,[6] Razi Cov Pars, Sanofi–GSK, Sinopharm CNBG, Skycovione, Soberana 02,[6] Soberana Plus, V-01, and ZF2001.[6]
- one virus-like particle vaccine: CoVLP[6]
This article needs more reliable medical references for verification or relies too heavily on primary sources. (January 2023) |
Further information: COVID-19 vaccine
As of June 2022[update], 353 vaccine candidates are in various stages of development, with 135 in clinical research, including 38 in phase I trials, 32 in phase I–II trials, 39 in phase III trials, and 9 in phase IV development.[1]